Pricing Log in Create free account
Friday 6 November 2026 Export ITGR’s income statement to Excel — free account

Integer Holdings Corporation

ITGR Healthcare Medical Devices

Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024.

Revenue
−3.86%
EPS
−61.0%
Free cash flow
−65.2%
Total debt
+4.06%

Quarter to September 2026, against a year earlier

126.65 0.10 −0.08%
Market cap
$4.3B
P/E
42.2×
Fwd P/E
38.9×
Dividend yield
—
F-score
6/9
Altman Z
2.34
Beneish M
−2.30
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 5.24
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 — — — — — 2 — —
Insider Ownership 14.66%

Capital & Financial Ratios $m

Size
Market Cap 4,310.00
Revenue ttm 1,825.41
Net income ttm 103.70
Free cash flow ttm 81.82
Net debt Q 1,254.69
Valuation
P/E 42.22 (above 35: high)
Forward P/E 38.90 (above 35: high)
Price / sales 2.36
Forward P/S Powerpack
Price / FCF 53.33
Price / book 2.50
Financial health
Current ratio Q 3.98 (at or above 1.5: strong)
Debt / equity Q 0.74
Interest coverage Q 2.91
Growth
Revenue growth Q −3.86% (below 0%: shrinking)
Operating income growth Q −50.02% (below 0%: shrinking)
EPS, this year −5.02% (below 0%: weak)
EPS, next year A +12.88%
Revenue, next year A −1.76% (below 0%: weak)
EPS, past 5 yrs +4.40%
EPS, next 5 yrs A +4.53%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.0×, against a ten-year median of 2.8×; over the ten years it ranged from 1.8× in 2016 to 3.7× in 2018.
P/E against its own 10 years 81.45%
10-year low 10-year high
P/S against its own 10 years 80.05%
10-year low 10-year high
P/B against its own 10 years 84.64%
10-year low 10-year high
EV/Sales against its own 10 years 72.61%
10-year low 10-year high
EV/FCF against its own 10 years 78.91%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 24 47 17 14
Receivables 231 245 346 345
Inventory 229 247 254 279
Other 86 104 113 119
618 671 770 801
2023 2024 2025 Q'26
Payables 118 101 113 111
ST’ Debt — 10 — —
Other — — — —
221 227 232 201

Compound Annual Growth %

10y 5y 3y
Sales 8.76% 11.54% 11.67%
Cash Flow 31.72% 1.58% 19.01%
Earnings 0.00% 5.88% 15.70%
Book Value 7.46% 6.56% 7.21%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 1.65 Actual 1.34

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 1.70 1.76 Beat by 0.06
Q1 FY26 1.21 1.20 Miss by 0.01
Q2 FY26 1.38 1.60 Beat by 0.22
Q3 FY26 1.65 1.34 Miss by 0.31
Q4 FY26 1.75 — Reports 18 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.48 0.69 0.43 — —
’25 (0.66) 1.04 1.11 1.38 2.89
’24 0.59 0.88 0.99 0.90 3.36
’23 0.39 0.71 0.81 0.78 2.69
’22 0.34 0.62 0.48 0.54 1.99
’21 0.65 0.89 0.66 0.71 2.91
’20 0.94 0.01 0.92 0.47 2.33
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 440 464 450 — —
’25 437 476 468 472 1,854
’24 408 428 431 449 1,717
’23 379 400 397 380 1,556
’22 311 350 343 328 1,331
’21 290 312 306 313 1,221
’20 328 240 236 269 1,073
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 25 60 37 — —
’25 31 44 66 55 196
’24 23 47 72 63 205
’23 6 56 62 56 180
’22 18 19 28 52 116
’21 36 32 49 39 157
’20 32 46 32 71 181
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 37 16 — —
’25 6 25 46 28 105
’24 (6) 16 45 44 100
’23 (19) 23 37 18 60
’22 8 7 7 20 42
’21 29 22 37 16 104
’20 14 33 23 59 130
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1,076 1,136 1,215 1,258 1,073 1,221 1,331 1,556 1,717 1,854 1,825 +6.2% 1,821 1,929 2,034 +3.1%
Gross margin, % 31.40 31.16 29.85 28.22 26.62 27.60 25.97 26.35 26.74 26.99 24.59 (4.4) pt
EBT 28 49 61 105 86 101 69 105 148 125 108 +18.0%
EBT margin, % 2.62 4.34 5.03 8.36 8.03 8.28 5.16 6.77 8.60 6.76 5.91 +4.1 pt
Net income 6 67 168 96 77 97 66 91 120 103 104 +37.2%
Per share, $
Per share, $ Revenue 34.94 36.18 37.81 38.56 32.68 37.01 40.19 46.69 51.09 53.37 53.65 +4.8%
Earnings 0.19 2.12 5.23 2.95 2.35 2.93 2.00 2.72 3.57 2.96 3.00 +35.7%
Cash flow 3.43 4.76 5.21 5.07 5.52 4.75 3.51 5.41 6.11 5.65 5.19 +5.7%
Capex (1.89) (1.49) (1.35) (1.48) (1.56) (1.61) (2.24) (3.60) (3.14) (2.62) (2.78) +3.7%
Free cash flow 1.54 3.27 3.85 3.59 3.96 3.14 1.28 1.81 2.96 3.03 2.40 +7.8%
Book value 23.56 28.45 33.00 35.32 38.70 41.06 42.79 45.59 48.19 50.28 50.74 +8.8%
Shares, m 31 31 32 33 33 33 33 33 34 35 34 +1.4%
Valuation, ×
Valuation, × P/E 155.53 21.62 14.67 27.17 34.55 29.21 34.24 36.12 37.22 26.86 42.22 41.7
P/S 0.85 1.25 2.02 2.09 2.48 2.31 1.70 2.10 2.59 1.47 2.36 1.9
P/B 1.25 1.60 2.31 2.28 2.10 2.08 1.60 2.15 2.75 1.56 2.50 2.0
EV/Sales 2.41 2.64 2.76 2.72 3.12 2.98 2.39 2.72 3.16 2.12 3.05 2.7
EV/FCF 54.77 29.24 27.07 29.23 25.76 36.77 84.31 75.98 54.83 37.66 68.86 45.6
Cash, $m
Cash, $m Operating cash flow 106 149 167 165 181 157 116 180 205 196 176 +7.1%
Capex (58) (47) (44) (48) (51) (53) (74) (120) (106) (91) (95) +5.1%
Free cash flow 47 103 124 117 130 104 42 60 100 105 82 +9.3%
Balance, $m
Balance, $m Working capital 332 323 252 236 257 293 335 397 444 538 600 +5.5%
Net debt 1,678 1,572 900 801 682 818 909 947 967 1,197 1,255 (3.7%)
Shareholders’ equity 725 893 1,060 1,152 1,271 1,355 1,417 1,519 1,619 1,747 1,726 +10.3%
Returns, %
Returns, % ROA 0.21 2.35 6.49 4.12 3.27 3.91 2.47 3.16 3.98 3.17 3.05 +3.0 pt
ROIC 2.42 3.19 4.96 5.04 3.86 3.90 3.03 4.14 5.03 4.70 3.16 +2.3 pt
ROE 0.76 8.24 17.19 8.71 6.38 7.37 4.79 6.17 7.64 6.11 5.97 +5.4 pt
People
People Employees 9,400 9,700 8,250 8,250 7,500 9,000 10,000 10,500 11,000 11,000 — +1.8%
Revenue/emp, $m 0.11 0.12 0.15 0.15 0.14 0.14 0.13 0.15 0.16 0.17 — +4.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Integer Holdings Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TXG 10x Genomics $7.6B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%) Compare
HAE Haemonetics Corporation $5.7B 54.5× 30.2× +9.30% (above 0%: growing) +25.93% (above 0%: growing) +20.37% (above 0%: growing) 61.75% 21.00% Compare
LIVN LivaNova PLC $5.0B 25.6× 19.8× +9.88% (above 0%: growing) +27.41% (above 0%: growing) −30.95% (below 0%: shrinking) 67.41% 7.22% Compare
ITGR Integer Holdings Corporation $4.3B 42.2× 38.9× −3.86% (below 0%: shrinking) −61.04% (below 0%: shrinking) −65.19% (below 0%: shrinking) 22.59% 6.27%
IRTC iRhythm Holdings, Inc. $4.3B — (loss-making) — (loss-making) +14.88% (above 0%: growing) n/m −157.58% (below 0%: shrinking) 74.23% (14.69%) Compare
AXGN AxoGen, Inc. $2.9B — (loss-making) — (loss-making) +26.22% (above 0%: growing) +163.16% (above 0%: growing) +994.99% (above 0%: growing) 74.81% 1.26% Compare
NEOG Neogen Corporation $2.6B — (loss-making) — (loss-making) +6.50% (above 0%: growing) n/m +135.61% (above 0%: growing) 47.35% (0.81%) Compare
TMDX TransMedics Group, Inc. $2.4B 16.4× 49.4× +41.15% (above 0%: growing) −30.99% (below 0%: shrinking) −55.44% (below 0%: shrinking) 58.45% 13.86% Compare
UFPT UFP Technologies, Inc. $2.3B 30.1× 29.2× +11.57% (above 0%: growing) +25.55% (above 0%: growing) −35.77% (below 0%: shrinking) 29.44% 16.01% Compare
Median of peers $3.6B 27.8× 29.7× +10.73% +25.93% −17.78% 64.58% 4.24%

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 6 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 8.68m — 163.22
2023 8.74m — 122.03
2022 11.50m — 84.32
2021 6.92m — 105.42

Ownership

Directors and executive officers, together 1.10%
BlackRock, Inc. 15.06%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Integer Holdings Corporation (ITGR) Latest News

30 Oct

Impact 3 · · Simply Wall St.

29 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · StockStory
Impact 3 · · Zacks
Impact 3 · · Associated Press

22 Oct

Impact 4 · · Simply Wall St.

21 Oct

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

13 Oct

Impact 5 · · Insider Monkey

12 Oct

Impact 3 · · StockStory

7 Oct

Impact 3 · · Zacks

2 Oct

Impact 3 · · GlobeNewswire

30 Sep

Impact 4 · · GlobeNewswire

29 Sep

Impact 4 · · Zacks

4 Sep

Impact 5 ·

10 Aug

Impact 3 ·

6 Aug

Impact 4 ·

5 Aug

Impact 4 ·

4 Aug

Impact 5 · · medicaldevice-network.com
Impact 5 · · hospitalmanagement.net
Impact 4 ·

3 Aug

Impact 5 ·
Impact 5 · · InvestorsHub
Impact 5 · · medtechdive.com
Impact 5 ·
Impact 5 ·
Impact 5 ·
Impact 4 ·
Impact 3 ·
Impact 3 ·

ITGR metrics, ten years each

stockrow.com/ITGR · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com